Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Updates on Chronic Coronary Syndrome
Author(s): Filippo Gurgoglione , Giampaolo Niccoli Added: 7 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
ECG Exercise Stress Test in Coronary Artery Disease
Author(s): Gaetano Antonio Lanza Added: 2 weeks ago

Guidelines & Statements
Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease
Author(s): Federica Piani , Lorenzo Annesi , Claudio Borghi Added: 1 week ago

Heart Failure

Prevention & Chronic Conditions
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 7 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Gaps in Modern Heart Failure and Chronic Kidney Disease Research
Author(s): Simran Singh Parmar , Vasantha Muthuppalaniappan , Debasish Banerjee Added: 1 year ago

Heart Failure

Cardiovascular Renal Metabolic
Management of Left Main Coronary Artery Disease
Author(s): Gabriel Torres-Ruiz , Nuria Mallofré-Vila , Paola Rojas-Flores , et al Added: 1 year ago

Intervention

Prevention & Chronic Conditions
NF-kB in Cardiovascular Disease
Author(s): Akira Matsumori Added: 2 years ago

Vascular Disease and Surgery

Imaging & Diagnostics
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin
Author(s): William Herrington Added: 1 week ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,… View more

Cardiovascular Renal Metabolic
Author(s): Chim C Lang Added: 3 days ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists. View more

Cardiovascular Renal Metabolic
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 2 weeks ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Renal Metabolic